Highly Augmented Drug Loading and Stability of Micellar Nanocomplexes Composed of Doxorubicin and Poly(ethylene glycol)–Green Tea Catechin Conjugate for Cancer Therapy

Low drug loading and instability in blood circulation are two key challenges that impede the successful clinical translation of nanomedicine, as they result in only marginal therapeutic efficacy and toxic side effects associated with premature drug leakage, respectively. Herein, highly stable and ultrahigh drug loading micellar nanocomplexes (MNCs) based on the self‐assembly of the anticancer drug doxorubicin (DOX) and a poly(ethylene glycol)–epigallocatechin‐3‐O‐gallate (EGCG) conjugate are developed. The formation of these MNCs is facilitated by strong favorable intermolecular interactions between the structurally similar aromatic EGCG and DOX molecules, which impart exceptionally high drug‐loading capability of up to 88% and excellent thermodynamic and kinetic stability. Unlike two clinical formulations of DOX—free DOX and liposomal DOX, which are not effective below their lethal dosages, these DOX‐loaded MNCs demonstrate significant tumor growth inhibition in vivo on a human liver cancer xenograft mouse model with minimal unwanted toxicity. Overall, these MNCs can represent a safe and effective strategy to deliver DOX for cancer therapy. Self‐assembled micellar nanocomplexes (MNCs) leverage the favorable interaction between the structurally similar green tea catechin (epigallocatechin‐3‐O‐gallate) and small‐molecular anticancer drug doxorubicin (DOX) to attain ultrahigh drug loading capacity and stability in circulation. These DOX‐loaded MNCs demonstrate significant antitumor activity with attenuated toxicity, enabling a safe and effective strategy for cancer therapy.